Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

JANX Janux Therapeutics Inc

29,78

-0,34 (-1,13%)

Nach Börsenschluss

Zuletzt aktualisiert: 21:51:00

Verzögert um 15 Minuten

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

01/02/2025

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

09/30/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Andrew Meyer

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Janux Therapeutics (NASDAQ:JANX)
Historical Stock Chart
Von Feb 2025 bis Mär 2025

Click Here for more Janux Therapeutics Charts.

Janux Therapeutics (NASDAQ:JANX)
Historical Stock Chart
Von Mär 2024 bis Mär 2025

Click Here for more Janux Therapeutics Charts.

News Janux Therapeutics Inc

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 6 März 2025 (3 Wochen vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Montag 3 März 2025 (3 Wochen vor) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Donnerstag 27 Februar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Donnerstag 27 Februar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 27 Februar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Donnerstag 27 Februar 2025 (4 Wochen vor) • Business Wire

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Freitag 14 Februar 2025 (1 Monat vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 6 Februar 2025 (2 Monate vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Montag 3 Februar 2025 (2 Monate vor) • Edgar (US Regulatory)

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer
Freitag 24 Januar 2025 (2 Monate vor) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 9 Januar 2025 (3 Monate vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Dienstag 7 Januar 2025 (3 Monate vor) • Edgar (US Regulatory)

Weitere Janux Therapeutics Inc News-Artikel

BNP Paribas (QX)

JP Morgan Chase

Health Care Select Sector

Deutsche Lufthansa

Financial Select Sector

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen